Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation.
biomarker
cholangiocarcinoma
diagnosis
extracellular vesicles
gallbladder cancer
hepatocellular carcinoma
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
received:
01
02
2020
revised:
12
06
2020
accepted:
24
06
2020
pubmed:
3
7
2020
medline:
22
6
2021
entrez:
3
7
2020
Statut:
ppublish
Résumé
Biliary cancer, comprising cholangio- and gallbladder carcinomas, is associated with high mortality due to asymptomatic disease onset and resulting late diagnosis. Currently, no robust diagnostic biomarker is clinically available. Therefore, we explored the feasibility of extracellular vesicles (EVs) as a liquid biopsy tool for biliary cancer screening and hepatobiliary cancer differentiation. Serum EVs of biliary cancer, hepatocellular carcinoma, colorectal cancer and non-small cell lung cancer patients, as well as from healthy individuals, were isolated by sequential two-step centrifugation and presence of indicated EVs was evaluated by fluorescence activated cell sorting (FACS) analysis. Two directly tumour-related antigen combinations (AnnV EV phenotyping, especially if combined with serum AFP, represents a minimally invasive, accurate liquid biopsy tool that could improve cancer screening and differential diagnosis of hepatobiliary malignancies.
Sections du résumé
BACKGROUND
Biliary cancer, comprising cholangio- and gallbladder carcinomas, is associated with high mortality due to asymptomatic disease onset and resulting late diagnosis. Currently, no robust diagnostic biomarker is clinically available. Therefore, we explored the feasibility of extracellular vesicles (EVs) as a liquid biopsy tool for biliary cancer screening and hepatobiliary cancer differentiation.
METHODS
Serum EVs of biliary cancer, hepatocellular carcinoma, colorectal cancer and non-small cell lung cancer patients, as well as from healthy individuals, were isolated by sequential two-step centrifugation and presence of indicated EVs was evaluated by fluorescence activated cell sorting (FACS) analysis.
RESULTS
Two directly tumour-related antigen combinations (AnnV
CONCLUSIONS
EV phenotyping, especially if combined with serum AFP, represents a minimally invasive, accurate liquid biopsy tool that could improve cancer screening and differential diagnosis of hepatobiliary malignancies.
Substances chimiques
alpha-Fetoproteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3103-3116Informations de copyright
© 2020 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Cancer.Net ASoCOA. Gallbladder cancer - medical illustrations. Cancernet Articles. 2012.
Lewis DR, Chen H-S, Cockburn MG , et al. Early estimates of SEER cancer incidence, 2014. Cancer. 2017;123(13):2524-2534.
Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261-280.
Lazcano-Ponce EC, Miquel JF, Munoz N, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51(6):349-364.
Guglielmi A, Ruzzenente A, Campagnaro T, et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg. 2009;33(6):1247-1254.
Levy AD, Murakata LA, Rohrmann Jr CA. Gallbladder carcinoma: radiologic-pathologic correlation. Radiographics. 2001;21(2):295-314; questionnaire, 549-255.
Lang H, Sotiropoulos GC, Frühauf NR, et al. Extended hepatectomy for intrahepatic cholangiocellular carcinoma (ICC): when is it worthwhile? Single center experience with 27 resections in 50 patients over a 5-year period. Ann Surg. 2005;241(1):134-143.
Julich-Haertel H, Urban SK, Krawczyk M, et al. Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma. J Hepatol. 2017;67:282-292.
Julich H, Willms A, Lukacs-Kornek V, Kornek M. Extracellular vesicle profiling and their use as potential disease specific biomarker. Front Immunol. 2014;5:1-6.
Arbelaiz A, Azkargorta M, Krawczyk M, et al. Serum extracellular vesicles contain protein biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Hepatology. 2017;66(4):1125-1143.
Melo SA, Luecke LB, Kahlert C, et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177-182.
Théry C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750.
Kornek M, Schuppan D. Microparticles: Modulators and biomarkers of liver disease. J Hepatol. 2012;57:1144-1146.
Shao H, Chung J, Balaj L, et al. Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy. Nat Med. 2012;18:1835-1840.
Mocan T, Simão AL, Castro RE, et al. Liquid biopsies in hepatocellular carcinoma: are we winning? J Clin Med. 2020;9(5).
Urban SK, Mocan T, Sanger H, Lukacs-Kornek V, Kornek M. Extracellular vesicles in liver diseases: diagnostic, prognostic, and therapeutic application. Semin Liver Dis. 2019;39(1):70-77.
Macias RIR, Kornek M, Rodrigues PM, et al. Diagnostic and prognostic biomarkers in cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):108-122.
Julich-Haertel H, Tiwari M, Mehrfeld C, Krause E, Kornek M, Lukacs-Kornek V. Isolation and enrichment of liver progenitor subsets identified by a novel surface marker combination. J Vis Exp. 2017(120).
Lukacs-Kornek V, Julich-Haertel H, Urban SK, Kornek M. Multi-surface antigen staining of larger extracellular vesicles. Methods Mol Biol. 2017;1660:201-208.
Gu MJ, Jang BI. Clinicopathologic significance of Sox2, CD44 and CD44v6 expression in intrahepatic cholangiocarcinoma. Pathol Oncol Res. 2014;20(3):655-660.
Eckert C, Kim YO, Julich H, et al. Podoplanin discriminates distinct stromal cell populations and a novel progenitor subset in the liver. American J Physiol-Gastrointestinal Liver Physiol. 2016;310:G1-G12.
Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283.
Quintanilla M, Montero-Montero L, Renart J, Martín-Villar E. Podoplanin in inflammation and cancer. Int J Mol Sci. 2019;20(3).
Cioca A, Ceausu AR, Marin I, Raica M, Cimpean AM. The multifaceted role of podoplanin expression in hepatocellular carcinoma. Eur J Histochem. 2017;61(1):2707.
Lötvall J, Hill AF, Hochberg F, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014;3:26913.
Ettelaie C, Collier ME, Maraveyas A, Ettelaie R. Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. J Extracell Vesicles. 2014;3.
Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018;68(2):723-750.
European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182-236.
Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28-v37.
Tian Y, Liu L, Yeolkar NV, Shen F, Li J, He Z. Diagnostic role of staging laparoscopy in a subset of biliary cancers: a meta-analysis. ANZ J Surg. 2017;87(1-2):22-27.
Wang W, Fei Y, Wang F. Meta-analysis of contrast-enhanced ultrasonography for the detection of gallbladder carcinoma. Med Ultrason. 2016;18(3):281-7.
Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-1289.
Dorobisz T, Dorobisz K, Chabowski M, et al. Incidental gallbladder cancer after cholecystectomy: 1990 to 2014. OncoTargets and Therapy. 2016;9:4913-4916.
Lukacs-Kornek V, Lammert F. The progenitor cell dilemma: Cellular and functional heterogeneity in assistance or escalation of liver injury. J Hepatol. 2017;66(3):619-630.
Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9(4):261-272.
Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene. 2006;25:3818-3822.
Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun. 2008;373(1):36-41.
Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007;96(3):417-423.
Willms A, Muller C, Julich H, et al. Tumour-associated circulating microparticles: a novel liquid biopsy tool for screening and therapy monitoring of colorectal carcinoma and other epithelial neoplasia. Oncotarget. 2016;7(21):30867-30875.
Jiang S, Pei L, Yang Z-L, Liu G. Prognostic value of the stem cell markers Epcam and CD133 expression of gallbladder adenocarcinoma. Hepatogastroenterology. 2014;61:574-579.
Wang J, Wu Y, Gao W, et al. Identification and characterization of CD133(+)CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines. J Cancer. 2017;8(3):497-506.
Yu J, Tang Z, Gong W, Zhang M, Quan Z. Isolation and identification of tumor-initiating cell properties in human gallbladder cancer cell lines using the marker cluster of differentiation 133. Oncol Lett. 2017;14(6):7111-7120.
Suzuki A, Sekiya S, Onishi M, et al. Flow cytometric isolation and clonal identification of self-renewing bipotent hepatic progenitor cells in adult mouse liver. Hepatology. 2008;48(6):1964-1978.
Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology. 1998;27:974-982.
Shi C, Tian R, Wang M, et al. CD44+ CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;10(11):1182-1190.
Yanagisawa N, Mikami T, Mitomi H, Saegusa M, Koike M, Okayasu I. CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation. Cancer. 2001;91:408-416.
Tsuchida A, Nagakawa Y, Kasuya K, et al. Significance of CD44s and CD44v6 expression in pancreaticobiliary maljunction. Hepatogastroenterology. 2011;58:1877-1881.
Rupesh P, Manoj P, Vijay KS. Biomarkers in carcinoma of the gallbladder. Expert Opin Med Diagn. 2008;2(5):511-526.
Banales JM, Iñarrairaegui M, Arbelaiz A, et al. Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis. Hepatology. 2019;70(2):547-562.